
Patrick M Winter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/466876/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	Editorial for "Nonâ€enhanced Chemical Exchange Saturation Transfer Cardiac Magnetic Resonance Imaging in Patients With Amyloid Light Chain Amyloidosis― Journal of Magnetic Resonance Imaging, 2022, 55, 577-578.	3.4	0
2	Initial investigation of a novel noninvasive weight loss therapy using MRIâ€Guided high intensity focused ultrasound (MRâ€HIFU) of visceral fat. Magnetic Resonance in Medicine, 2016, 76, 282-289.	3.0	6
3	Perfluorocarbon Nanoparticles. , 2016, , 3143-3156.		0
4	Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine. Journal of Magnetic Resonance Imaging, 2015, 41, 1079-1087.	3.4	16
5	Perfluorocarbon Nanoparticles: Evolution of a Multimodality and Multifunctional Imaging Agent. Scientifica, 2014, 2014, 1-10.	1.7	16
6	Molecular Imaging at Nanoscale with Magnetic Resonance Imaging. , 2014, , 75-102.		0
7	Molecular MR Imaging of Neovascular Progression in the Vx2 Tumor with αvβ3-Targeted Paramagnetic Nanoparticles. Radiology, 2013, 268, 470-480.	7.3	37
8	An MRI system for imaging neonates in the NICU: initial feasibility study. Pediatric Radiology, 2012, 42, 1347-1356.	2.0	43
9	Magnetic resonance chemical exchange saturation transfer imaging and nanotechnology. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2012, 4, 389-398.	6.1	16
10	Quantification of water exchange kinetics for targeted PARACEST perfluorocarbon nanoparticles. NMR in Biomedicine, 2012, 25, 279-285.	2.8	12
11	Magnetic Resonance Molecular Imaging of Plaque Angiogenesis. Current Cardiovascular Imaging Reports, 2012, 5, 36-44.	0.6	0
12	Research Highlights. Nanomedicine, 2011, 6, 1305-1308.	3.3	0
13	Tuning of the drug delivery vehicle. Nanomedicine, 2011, 6, 1306.	3.3	0
14	Improving the homogeneity of DNA patterning on microarrays. Nanomedicine, 2011, 6, 1306-7.	3.3	0
15	Targeted nanoparticles for phototherapy. Nanomedicine, 2011, 6, 1307.	3.3	0
16	Advantages of a positive surface charge. Nanomedicine, 2011, 6, 1308.	3.3	0
17	Angiogenesis imaging with vascular-constrained particles: the why and how. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 114-126.	6.4	33
18	Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis, 2010, 13, 189-202.	7.2	95

#	Article	IF	CITATIONS
19	Assessment of tumor angiogenesis: dynamic contrastâ€enhanced MRI with paramagnetic nanoparticles compared with Gdâ€DTPA in a rabbit Vxâ€2 tumor model. Contrast Media and Molecular Imaging, 2010, 5, 155-161.	0.8	9
20	Molecular imaging of angiogenic therapy in peripheral vascular disease with α _ν ̲ ₃ â€integrinâ€targeted nanoparticles. Magnetic Resonance in Medicine, 2010, 6 369-376.	94,3.0	55
21	Quantitative cardiovascular magnetic resonance for molecular imaging. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 62.	3.3	20
22	Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Medicinal Chemistry, 2010, 2, 471-490.	2.3	88
23	MR Molecular Imaging of Aortic Angiogenesis. JACC: Cardiovascular Imaging, 2010, 3, 824-832.	5.3	26
24	Antiâ€angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009, 1, 311-323.	6.1	45
25	Gadoliniumâ€modulated ¹⁹ F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magnetic Resonance in Medicine, 2008, 60, 1066-1072.	3.0	86
26	Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magnetic Resonance in Medicine, 2008, 60, 1353-1361.	3.0	55
27	Antiangiogenic Synergism of Integrin-Targeted Fumagillin Nanoparticles and Atorvastatin in Atherosclerosis. JACC: Cardiovascular Imaging, 2008, 1, 624-634.	5.3	142
28	Minute dosages of α <i>_ν</i> β ₃ â€ŧargeted fumagillin nanoparticles impair Vxâ€⊋ tumor angiogenesis and development in rabbits. FASEB Journal, 2008, 22, 2758-2767.	0.5	102
29	Magnetic Resonance Molecular Imaging and Targeted Therapeutics. , 2008, , 649-672.		0
30	Molecular MR Imaging with Paramagnetic Perfluorocarbon Nanoparticles. , 2008, , 163-182.		0
31	Emerging nanomedicine opportunities with perfluorocarbon nanoparticles. Expert Review of Medical Devices, 2007, 4, 137-145.	2.8	67
32	Spectral properties of a bifunctional PARACEST europium chelate: an intermediate for targeted imaging applications. Contrast Media and Molecular Imaging, 2007, 2, 55-58.	0.8	25
33	Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. Journal of Magnetic Resonance Imaging, 2007, 25, 667-680.	3.4	186
34	Targeted nanoparticle contrast agents for vascular molecular imaging and therapy. , 2007, , 289-302.		0
35	Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. International Journal of Nanomedicine, 2007, 2, 515-26.	6.7	61
36	In Vitro Demonstration Using 19F Magnetic Resonance to Augment Molecular Imaging With Paramagnetic Perfluorocarbon Nanoparticles at 1.5 Tesla. Investigative Radiology, 2006, 41, 305-312.	6.2	93

PATRICK M WINTER

#	Article	IF	CITATIONS
37	Nanomedicine Opportunities in Cardiology. Annals of the New York Academy of Sciences, 2006, 1080, 451-465.	3.8	33
38	Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine, 2006, 1, 321-329.	3.3	61
39	Molecular imaging by MRI. Current Cardiology Reports, 2006, 8, 65-69.	2.9	38
40	Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magnetic Resonance in Medicine, 2006, 56, 1384-1388.	3.0	97
41	Targeted Magnetic Resonance Imaging Contrast Agents. , 2006, 124, 387-400.		29
42	Endothelial α ν β 3 Integrin–Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2103-2109.	2.4	382
43	Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 435-441.	2.4	153
44	Improved paramagnetic chelate for molecular imaging with MRI. Journal of Magnetism and Magnetic Materials, 2005, 293, 540-545.	2.3	42
45	Nanotechnologies for Cellular and Molecular Imaging by MRI. , 2005, , 227-249.		5
46	Molecular MR imaging of melanoma angiogenesis with ???3-targeted paramagnetic nanoparticles. Magnetic Resonance in Medicine, 2005, 53, 621-627.	3.0	266
47	Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Review of Cardiovascular Therapy, 2005, 3, 705-715.	1.5	38
48	Molecular Imaging of Human Thrombus with Computed Tomography. Academic Radiology, 2005, 12, S9-S13.	2.5	58
49	1H/19F Magnetic Resonance Molecular Imaging with Perfluorocarbon Nanoparticles. Current Topics in Developmental Biology, 2005, 70, 57-76.	2.2	62
50	Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magnetic Resonance in Medicine, 2004, 51, 480-486.	3.0	252
51	Quantitative ?magnetic resonance immunohistochemistry? with ligand-targeted19F nanoparticles. Magnetic Resonance in Medicine, 2004, 52, 1255-1262.	3.0	200
52	Magnetic resonance molecular imaging with nanoparticles. Journal of Nuclear Cardiology, 2004, 11, 733-743.	2.1	125
53	Novel Paramagnetic Contrast Agents for Molecular Imaging and Targeted Drug Delivery. Current Pharmaceutical Biotechnology, 2004, 5, 495-507.	1.6	48
54	Improved molecular imaging contrast agent for detection of human thrombus. Magnetic Resonance in Medicine, 2003, 50, 411-416.	3.0	195

PATRICK M WINTER

0

#	Article	IF	CITATIONS
55	Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With α _v β ₃ -Integrin–Targeted Nanoparticles. Circulation, 2003, 108, 2270-2274.	1.6	691
56	Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Research, 2003, 63, 5838-43.	0.9	323
57	Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent. Circulation, 2002, 106, 2842-2847.	1.6	274
58	Molecular Imaging and Targeted Drug Delivery with a Novel, Ligand-Directed Paramagnetic Nanoparticle Technology. Academic Radiology, 2002, 9, S330-S331.	2.5	38
59	A Novel Europium(III)-Based MRI Contrast Agent. Journal of the American Chemical Society, 2001, 123, 1517-1518.	13.7	257
60	Triple-Quantum-Filtered 23Na NMR Spectroscopy of Subcutaneously Implanted 9L Gliosarcoma in the Rat in the Presence of TmDOTP5â°'. Journal of Magnetic Resonance, 2001, 152, 70-78.	2.1	33
61	TmDOTP5- as a23Na shift reagent for the subcutaneously implanted 9L gliosarcoma in rats. Magnetic Resonance in Medicine, 2001, 45, 436-442.	3.0	57
62	Novel MRI Contrast Agent for Molecular Imaging of Fibrin. Circulation, 2001, 104, 1280-1285.	1.6	540
63	Quantitation of intracellular [Na ⁺] in vivo by using TmDOTP ^{5â^'} as an NMR shift reagent and extracellular marker. Jour 1998, 85, 1806-1812.	mæ !.o f App	liedsPhysiolo

Diagnostic and Therapeutic Targeted Perfluorocarbon Nanoparticles. , 0, , 365-380.